Furthermore, fluoxetine decreased the production of IL‐1β, IL‐6, and IL‐17 by activated CD4+ and CD8+ T-cells, suggesting an anti-inflammatory effect of treatment with fluoxetine on Th17-immune response in relapsing-remitting MS patients with MDD (49). The gene discussed is IL17A; the disease is relapsing-remitting multiple sclerosis.